FDA Contracts with ISMP on Medication Errors

FDA has approved an additional contract with the Institute for Safe Medication Practices (ISMP) to provide expert analysis and data-driven insights to strengthen the agency’s ability to identify and reduce the risk of medication errors. ISMP says it will collaborate with CDER to advance postmarket surveillance, identify potential causes and contributing factors of medication errors, and help develop strategies to prevent patient harm.

IMSP says its services under the contract will include:

• access to anonymous reports from ISMP national reporting programs;
• in-depth report analysis to assist the agency in evaluating product safety;
• expert consultation on medication error risk identification and mitigation strategies;
• customized surveillance reports in response to emerging safety concerns; and
• alerting the agency about emerging medication safety issues and concerning trends.